Artiva Biotherapeutics posts 2025 results, prepares for RA clinical data in early 2026

Traders Union
All News
Companies
Artiva posts 2025 results outlook

Top Stories

Editors' Picks

Crypto News

Financial News

Currencies

Market Voices

Companies

Regulators News

10.03.2026

Artiva Biotherapeutics posts 2025 results, prepares for RA clinical data in early 2026 — Artiva posts 2025 results outlook

Artiva Biotherapeutics reported full year 2025 financial results and outlined progress on its AlloNK program for autoimmune diseases.

The company expects initial clinical response data from at least 15 refractory rheumatoid arthritis patients in the first half of 2026. Additionally, Artiva Biotherapeutics plans an upcoming interaction with the FDA to further discuss the development pathway for AlloNK in autoimmune disorders. Details regarding financial performance and forthcoming milestones were not disclosed in the initial update.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

From “Holy Trinity” to WLD crash: How Arthur Hayes became a market-moving seller

By Mikhail Vnuchkov
20 hours ago

From “Holy Trinity” to WLD crash: How Arthur Hayes became a market-moving seller

Editors' Picks

The world's first trillionaire: How Musk built his fortune on electric cars, space and AI

By Eugene Komchuk
Yesterday

The world's first trillionaire: How Musk built his fortune on electric cars, space and AI

Editors' Picks

How precious-metals mining revival is reshaping portfolios in 2026

By Ciaran Ryan
11.06.2026

How precious-metals mining revival is reshaping portfolios in 2026

Editors' Picks

All Editors' Top Picks

Latest Artiva News

FDA awards Artiva Biotherapeutics, Inc. RMAT status for AlloNK combination therapy in rheumatoid arthritis

By Ivan Andriyenko
08.06.2026

FDA awards Artiva Biotherapeutics, Inc. RMAT status for AlloNK combination therapy in rheumatoid arthritis

Companies

$Artiva Biotherapeutics aims for first Phase 3 trial targeting B-cell depletion in refractory rheumatoid arthritis$

By Andreas Kristo
04.06.2026

Artiva Biotherapeutics aims for first Phase 3 trial targeting B-cell depletion in refractory rheumatoid arthritis

Companies

Artiva Biotherapeutics, Inc. to outline AlloNK Phase 3 progress at New York Jefferies event

By Oleg Tkachenko
28.05.2026

Artiva Biotherapeutics, Inc. to outline AlloNK Phase 3 progress at New York Jefferies event

Companies

All Artiva News

Mikhail Vnuchkov
20 hours ago

From “Holy Trinity” to WLD crash: How Arthur Hayes became a market-moving seller

Eugene Komchuk
Yesterday

The world's first trillionaire: How Musk built his fortune on electric cars, space and AI

Ciaran Ryan
11.06.2026

How precious-metals mining revival is reshaping portfolios in 2026

Mikhail Vnuchkov
11.06.2026

Bitcoin price prediction after CPI rise: Is BTC headed for deeper losses?

Eugene Komchuk
10.06.2026

Five years with Bitcoin: How El Salvador changed after legalizing BTC

Jose Antonio Gastelum
1 hour ago

Equity ownership remains relevant if Bitcoin is money, Adam Livingston argues

Andrey Mastykin
1 hour ago

Knicks owner stock has seen strong gains this year, Steve Hou notes

Anastasiia Chabaniuk
1 hour ago

James Pethokoukis: SpaceX valuation surge driven by public perception of Musk

Daria Chernytska
1 hour ago

Alex Svanevik: Nansen AI agent enables trading via Hyperliquid, Solana, or Base

Eugene Komchuk
2 hours ago

Crude oil may follow major historical declines, Mike McGlone warns

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Mikhail Vnuchkov
20 hours ago

From “Holy Trinity” to WLD crash: How Arthur Hayes became a market-moving seller

From “Holy Trinity” to WLD crash: How Arthur Hayes became a market-moving seller

Eugene Komchuk
Yesterday

Sam Bankman-Fried fails to challenge FTX conviction

Sam Bankman-Fried fails to challenge FTX conviction

Olga Shendetskaya
Yesterday

BlackRock loses ETF lead as Vanguard fund inflows accelerate

BlackRock loses ETF lead as Vanguard fund inflows accelerate

Igor Krasulya
Yesterday

AI executives to discuss technology risks at G7 summit

AI executives to discuss technology risks at G7 summit

Eugene Komchuk
Yesterday

Traders Union research: 31% of market participants invest for financial independence

Traders Union research: 31% of market participants invest for financial independence

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Microsoft slides again as capex continues to weigh on shares

Anton Kharitonov
Now

Apple recovers as improving risk appetite boosts demand for equities

Mykhailo Ihnatenko
Now

Moderna eyes breakout as investors focus on its next growth drivers

Anton Kharitonov
Now

Bitcoin recovers as risk appetite improves despite weak institutional demand

Anton Kharitonov
Now

WTI continues to decline amid progress in U.S.-Iran talks

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.